Trametinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TRAMETINIB |
|---|---|
| Type | Drug |
| Aliases | MekinistТраметиніб |
| Status | pending_clinical_signoff |
| Diseases | DIS-MELANOMA DIS-NSCLC DIS-THYROID-ANAPLASTIC |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | MEK1/2 inhibitor |
|---|---|
| Mechanism | Selective MEK inhibitor used in combination with dabrafenib. Reduces resistance + skin toxicity vs BRAFi alone. |
| Typical dosing | 2 mg PO once daily + dabrafenib 150 mg BID. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Always combined with dabrafenib for BRAF V600E NSCLC, melanoma, ATC. Cardiac monitoring critical.
Used By
Regimens
REG-DAB-TRAM-ATC- Dabrafenib + trametinib (anaplastic thyroid carcinoma, BRAF V600E)REG-DABRAFENIB-TRAMETINIB-NSCLC- Dabrafenib + trametinib (BRAF V600E+ NSCLC)